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Abstract 
Background: CCL22 is a chemokine that induces the migration of Th2- and regulatory T cells to the inflammatory 
sites. The aim of this study was to investigate the association of a single nucleotide polymorphism (SNP), 
rs4359426, in CCL22 gene, with multiple sclerosis (MS) in patients from southeast of Iran. Materials and 
Methods: The blood samples collected from 150 patients with MS and 150 healthy subjects as a control group. The 
serum levels of CCL20 measured by ELISA and the DNA analyzed for CCL22 polymorphism using PCR-RFLP 
method. Results: There were no significant differences in the frequencies of genotypes and alleles at SNP 
rs4359426 in CCL22 gene between MS patients and controls. No significant differences also observed between 
controls and patients with RRMS, SPMS, PPMS and PRMS patterns regarding the genetic variation of  
rs4359426. In both MS and control groups, no significant differences were observed between subjects with CC, 
CA and AA genotypes or between subjects with C and A alleles concerning rs4359426 with respect to the serum 
levels of CCL22. Conclusion: These results do not show any association between the investigated genotypes and 
alleles at rs4359426 in CCL22 gene with MS or its patterns in MS patients. The serum levels of chemokine did not 
also influence by genetic variation of SNP rs4359426. 
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Multiple sclerosis (MS) is characterized  as a 
demyelinating disease of the human central nervous 
system (CNS). It’s etiology remains unknown, 
although genetic predisposition, environmental 
factors and autoimmune mechanisms play an 
important role in the pathogenesis of MS [1]. The 
MS clinical course is classified as relapsing-
remitting (RRMS), primary progressive (PPMS), 
progressive relapsing (PRMS) and secondary 
progressive (SPMS) [2]. The immunologic 
responses play key roles in the pathogenesis and 
complications of MS disease [3, 4]. Specifically, T-
helper (Th)-dependent responses, play an important 
role in the pathogenesis of MS disease (3). Upon 
antigenic stimulation, Th cells differentiate into 
Hajghani et al.                                                                                    CCL22 gene polymorphism in multiple sclerosis 
 Archives of Medical Laboratory Sciences 
46 
several subsets such as Th1, Th2, Th17 and 
regulatory T (Treg) cells which have been 
characterized by the release of distinct cytokines 
profile [5, 6]. It has been reported that the Th1- and 
Th17-mediated responses can lead to MS disease 
progression and worsening of symptoms whereas 
the Th2- and Treg-mediated responses have been 
associated with reduction of inflammation and 
improvement of symptoms in MS patients [4, 7, 8].  
The infiltration of leukocytes into the CNS is 
an essential step in the neuropathogenesis of MS 
disease that controls by chemokines [9]. 
Chemokines are classified into CXC, CC, CX3C or 
C chemokines based on the position  of the 
conserved cysteine residues [10]. Chemokine (C-C 
motif) ligand 22 (CCL22) or macrophage-derived 
chemokine (MDC) is a chemokine that is produced 
by macrophages and dendritic cells (DCs). The 
receptor for CCL22, named CC Chemokine receptor 
4 (CCR4) is  preferentially expressed on Th2 and 
Treg cells. Accordingly, CCL22 acts as a chemo 
attractant for the migration and accumulation of Th2 
and Treg cells into inflammatory sites [11, 12].  
The genetic variations in the CCL22 gene may 
also influence on  the serum levels of chemokine in 
MS patients. The gene of CCL22 chemokine has been 
located on the chromosome 16q13 with several SNPs 
in both coding and non-coding sequences, of which 
the SNP rs4359426 (16C/A) may influence the 
chemokine expression [13, 14]. The functional effect 
of SNP rs4359426 is changing of GAT to GCT in 
coding region which causes a 2 Asp to 2 Ala 
substitutions in the CCL22 protein [14]. We assumed 
that this SNP may have an association with MS 
disease. Accordingly, the aim of the present study was 
to investigate the association of SNP rs4359426 with 
MS disease and the serum levels of CCL22 in a 
population from the southeast of Iran to clarify any 
association. 
Methods 
Subjects. Blood samples were collected from 
150 patients with MS disease (mean age 35.72 ± 8.37 
years) during March to September 2013 in Shephah 
Hospital of Kerman (a city located in southeast of 
Iran). The expert neurologists confirmed the presence 
of MS, according to the clinical and paraclinical 
findings (MRI study, oligoclonal bands in CSF, and 
evoked potentials) based on McDonald’s criteria [15]. 
The patients were in the RRMS (n=76), SPMS 
(n=39), PPMS (n=20) or PRMS (n=15) course of 
disease.  
The control group consisted of 150 age-
matched healthy subjects, with no personal and 
familial history of MS disease (mean age 36.52 ± 
8.21). The healthy control subjects were recruited 
among blood donors of the Kerman Transfusion 
Organization and interviewed regarding the CNS 
disorders and none of them had any history of CNS or 
any other relevant disease.  
This study was evaluated and approved by the 
Ethical Committee of Kerman University of Medical 
Sciences. Moreover, patients were recruited if they 
agreed for blood sampling. A peripheral blood sample 
(4-5 milliliter) was obtained from all participants and 
the sera were separated and stored at 70°C until 
analysis.   
DNA Extraction and Genotype Analysis. 
DNA was extracted from peripheral blood leukocytes 
by salting out method as previously described by 
Miller et al. [16]. The quantity and the purity of DNA 
samples were determined by measuring the optical 
density at 260 and 280 nm wavelengths using 
spectrophotometry (Ependorf, Germany). DNA 
samples were stored at -20°C until use. Genotypes at 
position 16C/A in CCL22 (rs4359426; Asp2Ala) were 
determined by polymerase chain reaction–restriction 
length polymorphism (PCR–RFLP) method.   
The forward primer (5′-
CAAGTGACTCTGGGCACCCCA-3′) and reverse 
primer (5′-CTGCTCTTGGTCCAGTGCTTGTC-3′) 
were used to amplify the region around 16C/A SNP. 
PCR reaction mixture was made up of addition of the 
following reagents to a 0.2 ml microcentrifuge tube 
on ice: 2.5 μl of Taq DNA polymerase buffer (10×), 
0.5 μl of MgCl2 (stock concentration 1.5 mM), 0.5 μl 
of each dNTP [dATP, dCTP, dGTP, and dTTP (stock 
concentration of 10 mM)], 1 μl of each primer, 1 μl of 
prepared DNA, and sterile double-distilled water to a 
final volume of 25 μl. The amplification was 
performed with the following program: one cycle of 
94°C for 5 min, followed by 30 cycles of 94°C for 30 
s, 64°C for 20 s and 72°C for 30 s. The amplified 
PCR product of CCL20 gene covers rs4359426 with a 
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molecular size of 297 bp.  
The amplified products were then underwent 
restriction reaction in the presence of 5 IU of MboI 
restriction enzyme (Fermentas, Lithuania) overnight 
at 37°C. The digested products were electrophoresed 
on a 2.5% agarose gel after adding 4 μl of loading 
buffer (Cinnagen, Iran) and studied on Chemi-Doc 
model XRS (Bio-Rad, USA) after staining with 
ethidium bromide. The 297 bp product from 16C/A 
loci was cut into 164 and 133 bp fragments when A 
allele existed, but remained undigested if C allele was 
present at this position. In case of heterozygotic form 
(C/A), three different fragments with 297, 164 and 
133 bp are then visible. In homozygotic form, a 297 
bp fragment [without any digestion (C/C)] or two 164 
and 133 bp [digesting both alleles (A/A)] was 
observed.  
Chemokine Assay. The serum levels of CCL22 
were measured by ELISA (R&D systems, UK) in 
patients and healthy controls according to the 
manufacturer guidelines. The intra- and inter assay 
coefficient variations of test were <5% and 8%, 
respectively. 
Statistical Analysis. Hardy–Weinberg 
equilibrium was assessed using genotype data. Allele 
and genotype frequencies were calculated in patients 
and healthy controls by direct gene counting. 
Differences in variables were analyzed using Student 
t, ANOVA and χ2 tests as appropriate and P values of 
less than 0.05 were considered significant. The data 
were analyzed by SPSS 15 (SPSS Inc, Chicago, IL, 
USA) and Epi Info 2000 (CDC, Atlanta, Georgia, 
USA) software packages. 
Results 
Table 1 summarizes the frequencies of 
genotypes and alleles at SNP rs4359426 in CCL22 
gene in patients with MS and healthy control group. 
Statistical analysis showed no deviation of genotype 
frequencies from Hardy-Weinberg equilibrium, 
neither in the patients nor in the controls. Statistical 
analysis also revealed no significant differences in the 
frequencies of genotypes (CC, CA and AA 
genotypes) and alleles (C and A alleles) at SNP 
rs4359426 in CCL22 gene between MS patients and 
controls.  
The frequencies of genotypes and alleles at 
SNP rs4359426 in CCL22 gene in patients with 
different patterns of MS disease have been 
summarized in Table 2. Statistical analysis showed no 
significant differences between patients with RRMS, 
SPMS, PPMS and PRMS patterns regarding the 
frequencies of genotypes (CC, CA and AA 
genotypes) and alleles (C and A alleles) at SNP 
rs4359426 in CCL22 gene.  
The levels of chemokine CCL22 according to 
the genetic variations at SNP rs4359426 in CCL22 
gene have been demonstrated in Table 3. In both MS 
patients and healthy control group, no significant 
differences were observed between subjects with CC, 
CA and AA genotypes or between subjects with C 
and A alleles at SNP rs4359426 with respect to the 
mean serum levels of CCL22. 
Discussion 
In this study, the association of the SNP 
rs4359426 in CCL22 gene with MS disease has been 
investigated in MS patients from the southeast of 
Iran. Our results indicated that CC genotype is the 
most common genotype among patients and 
controls; with no significant different between these 
groups. The frequencies of other genotypes CA and 
AA in patient and control groups were also not 
significantly different. The minor allele frequency 
(MAF) in our population was also 0.02. Consistent 
with our study, the results of a study in Italian 
patients with MS indicate no significant association 
between SNP rs4359426 and MS disease; although, 
in the consideration of its relation with CCL17 
polymorphism, AT haploytype (CCL22 A, CCL17 
T) was significantly lower in MS patients than 
control group [17]. The MAF in this Italian sample 
was 0.04 which is slightly upper than our study. The 
results of the present study also showed no 
Table 1: The frequency of CCL22 gene polymorphism in 








CC 126 (84.0) 127 (84.7) 0.87 
CA 24 (16.0) 20 (13.3) 0.51 
AA 0 (0.0) 3 (2.0) 0.08 
C 276 (92.0) 274 (91.4) 0.67 
A 24 (8.0) 26 (8.6) 0.67 
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significant differences between patients with RRMS, 
SPMS, PPMS and PRMS patterns regarding the 
frequencies of genotypes (CC, CA and AA 
genotypes) and alleles (C and A alleles) SNP 
rs4359426 in CCL22 gene. Accordingly, we could 
not find any association between different genotypes 
at SNP rs4359426 and the MS disease or its pattern.  
The association of the SNP rs4359426 
(16C/A) with several diseases has been investigated 
in a number of studies. Recently, in two studies in 
southern Iranian population no correlation was 
found between the SNP rs4359426 in CCL22 gene 
with susceptibility to, and progression of breast 
cancer or colorectal cancer [18, 19]. The results of a 
study in a population from China demonstrated a 2.3 
times increase in the risk of gastric carcinoma 
among subjects who inherited Ala/Ala (AA) 
genotypes at SNP rs4359426 in CCL22 gene in 
comparison with other genotypes [14]. Janssen et al. 
were not able to indicate the association of the SNP 
rs4359426 with respiratory syncytial virus 
bronchiolitis in a population from Netherlands [20]. 
The discrepancy between the results of the different 
studies may be due to the differences in the 
etiopathological mechanisms of the investigated 
diseases, the differences in the study design, study 
sample size and finally the different genetic 
background of the investigated populations.  
It has been reported that C to A substitution at 
position 16 in exon 1 of CCL22 results in the 
substitution of 2 aspartate (2Asp) to 2 alanine (2Ala) 
in the N-terminal of the signal peptide of the CCL22 
protein [21]. The substitution of Asp by Ala at the 
N-terminal of signal peptide has been suggested to 
increase the net positive charge of the N-terminus, 
which potentially may lead to a higher level of 
CCL22 expression [22]. Moreover, as a negatively 
charged amino acid is replaced with a non-polar one, 
Table 2: The chemokine gene polymorphism in patients with MS according to disease patterns. 
 
Diseases pattern 
Genotypes [No. (%)] 
Total 
Alleles [No. (%)] 
CC CA AA C A 
RRMS 64 (84.2) 12 (15.8) 0 (00.0) 76 (100.0) 140 (92.1) 11 (7.9) 
SPMS 33 (84.6) 6 (15.4) 0 (00.0) 39 (100.0) 72 (92.3) 5 (7.7) 
PPMS 16 (80.0) 4 (20.0) 0 (00.0) 20 (100.0) 36 (90.0) 4 (10.0) 
PRMS 13 (86.7) 2 (13.3) 0 (00.0) 15 (100.0) 28 (93.3) 2 (6.7) 
Healthy 127 (84.7) 20 (13.3) 3 (2.0)  150 (100.0) 274 (91.4) 26 (8.6) 
 
 Table 3: Serum levels of CCL22 in MS patients and healthy subjects according to the chemokine gene 
polymorphism. 
Group Genotypes /Alleles No. (percent) 
CCL22 levels*  (mean ± 
SD) 
P value 
 MS patients      
CC 126 (84.0) 410.6 ± 24.51 
0.24 CA 24 (16.0) 338.33 ± 58.63 
Total  150 (100.0) 399.08 ± 22.65 
C 276 (92.0) 398.76 ± 22.80 
0.44 
A 24 (8.0) 338.33 ± 58.63 
Healthy control  
CC 127 (84.7) 419.88 ± 22.55 
0.60 
CA 20 (13.3) 362.83 ± 45.56 
AA 3 (2.0) 370.00 ± 110.0 
Total  150 (100.0) 411.26 ± 20.11 
C 274 (91.4) 419.88 ± 22.55 
0.45 
A 26 (8.6) 363.85 ± 40.49 
 
*The serum levels of chemokine expressed as Pg/ml. 
The P values represent the differences between different genotypes or alleles in a particular group.  
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an effect on the protein function would be 
conceivable which in turn affects its interaction with 
its CCR4 receptor. Accordingly, the variations in 
CCL22 may directly influence the activity of the 
protein.  
The association of this SNP in CCL22 gene 
with serum levels of CCL22 has been evaluated in 
the present investigation. However, our results 
indicated that in both MS and healthy control 
groups, no significant differences were observed 
between subjects with different genotypes or alleles 
at SNP rs4359426 with respect to the mean serum 
levels of chemokine CCL22. These data represent 
that the serum levels of CCL22 were not influenced 
by genetic variation at SNP rs4359426.  
In conclusion, the results of the present study 
do not indicate the association of SNP rs4359426 
(16C/A) in CCL22 gene with MS disease or its 
pattern in patients from southeast of Iran. The serum 
levels of chemokine did not also influence by genetic 
variation at SNP rs4359426. 
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